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This report describes the first biosynthetic analysis of the cystic fibrosis transmembrane conductance regulator (CFTR) in freshly excised
human rectal biopsies. Expression of functional CFTR was assessed by intestinal current measurement (ICM) prior to biosynthetic studies. Several
structural features of CFTR are found to be comparable to those established in CFTR-expressing cell lines. Interestingly, maturation of CFTR
increases substantially in tissue incubated at 26 °C. Our data provide a solid basis for future studies on the characterisation of CFTR in
pathological cases.
© 2006 Elsevier B.V. All rights reserved.Keywords: CFTR; Metabolic labelling; Immunoblot; Human tissueCystic fibrosis (CF) is the most common severe disease of
autosomal recessive inheritance in the Caucasian population. It
is caused by mutations in the CF transmembrane regulator
(CFTR) gene, which encodes a cAMP-regulated Cl− channel
that is expressed in the apical plasma membrane of exocrine
epithelia [1,2]. Most of our knowledge about human CFTR
resides on CFTR-expressing model systems such as immor-
talized or recombinant cell lines. Much less is known about the
structure, biosynthesis, processing and trafficking of CFTR in
native human tissue. CFTR biochemistry and function in
human tissue have been addressed in a few studies by
immunocytochemistry [2–9], immunoblot [6–9] and ion
transport analysis [10–13]. The limited amount of CFTR
expressed in native tissues as well as the lack of sufficiently
sensitive and specific anti-CFTR antibodies [6] have appar-
ently hampered metabolic labelling analysis in native human
tissue.
Here, we report on an ex vivo metabolic labelling [14] and
immunoblot study on freshly excised human rectal biopsies. In
the present study 2 to 4 specimens per volunteer were freshly
excised according to safety and ethical precautions. This study⁎ Corresponding author. Tel.: +49 511 532 6722; fax: +49 511 532 6723.
E-mail address: barneveld.andrea.van@mh-hannover.de (A. van Barneveld).
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Hannover, Germany and volunteers gave their written informed
consent. The suction device yields b2 mm in diameter epithelial
specimens that are devoid of submucosa and/or muscle [11].
Rectal biopsies are epithelial in nature, express CFTR as a
major chloride channel and are accessible by a harmless and
non-invasive procedure [6,12]. Moreover, a standardized
intestinal current measurement (ICM) protocol enables to
determine tissue viability and CFTR activity of the individual
freshly excised biopsy [11,12,16,17]. CFTR is recognized in
ICM by its electrophysiological profile of DIDS (4,4′-
diisothiocyanostilbene-2,2′-disulfonic acid)-insensitive secreto-
ry responses to forskolin/cAMP and cholinergic agonists (i.e.,
carbachol and histamine, Fig. 1A) [12,17]. Fig. 1 shows the
tracings of tissues obtained from a volunteer (Fig. 1A) and for
comparison from a CF patient lacking any chloride secretion
(Fig. 1B) [18]. Please note that the signal evoked by addition of
carbachol, 8-bromo-cAMP/forskolin or histamine represents a
superposition of chloride and potassium efflux. An upward
response indicates the net chloride efflux (Fig. 1A), whereas the
downward response reflects the potassium efflux in individuals
lacking CFTR (Fig. 1B) [11].
Prior to metabolic labelling or immunoblot analysis, the
biopsies from all 22 volunteers between 2 and 60 years were
Table 1
ICM data of the rectal biopsy specimens obtained from 22 volunteers (2 to 60






23.9±9.3 Ω · cm2
Basal Isc 55.8±30.1 μA/cm
2
ΔIsc amiloride −5.2±8.5 μA/cm2
ΔIsc carbachol 29.9±13.5 μA/cm
2 43.3±17.6 a μA/cm2 [12]
35.1±2.6 b μA/cm2 b18 years
old [16]
b 2
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et al. [12]. Normal chloride secretory responses upon exposure
to carbachol, forskolin or histamine insensitive to DIDS were
detected indicating normal activities of CFTR (Table 1, Fig.
1A). All biopsies that successfully passed the ICM experiment,
were included into the biochemical analysis.
During the 2 h of ICM the biopsy samples were incubated in
Meyler buffer that is supplemented with glucose as the only
carbon source. Hence, immediate biosynthetic labelling of two
rectal biopsy specimens with 35S-cysteine and 35S-methionine





ΔIsc histamine 29.8±22.4 μA/cm
2 39.3±19.3a μA/cm2 [12]
a Mean±standard deviation.
b Mean±standard error of mean.and methionine-free medium and was followed by detergent
extraction of the membrane proteins. Immunoprecipitation of
the extracts with the polyclonal anti-CFTR antibody R453
and the mononoclonal anti-CFTR antibodies M3A7 and
L12B4 [2,15] revealed two main molecular forms of CFTR
upon analysis by SDS-PAGE. These forms had approximate
apparent molecular masses of ~165 kDa and 195 kDa (Fig. 2,
lane a) and correspond therefore to the mannose-rich (B-band)
and complex-glycosylated (C-band) isoforms of CFTR. The
identity of the biosynthetic glycoforms in the biopsy samples
was assessed by direct comparison with the CFTR isoforms
immunoprecipitated with R453 antibody from T84 cells and
treated with endo-β-N-acetylglycosaminidase H and endo-β-
N-acetylglycosaminidase/N-glycosidase F (data not shown).
As a suitable control for efficiency of the metabolic labelling,
proper processing of glycoproteins and hitherto integrity of the
tissue during labelling we utilized the membrane glycoprotein
sucrase-isomaltase (SI) that has been extensively characterized
in human duodenal biopsy specimens [19]. In intestinal biopsy
specimens, two major biosynthetic forms of SI are revealed, a
mannose-rich 210 kDa (Pro-SIh) precursor and a 245-kDaFig. 1. ICM tracings of rectal suction biopsies obtained from (A) a healthy
volunteer and (B) a CF-patient. An upward response denotes net chloride
secretion (observed seen in panel A, but not in panel B), a downward response
denotes net potassium secretion (observed in the CF condition only) [11]. ICM
[12]: The electrogenic transport of ions across the intestinal epithelium was
measured as short circuit current (Isc) on biopsies of the rectal mucosa and
mounted into an adapted micro Ussing chamber with an aperture of 1.13 mm2.
The tissue was perfused in Meyler Buffer (126.2 mmol/l Na+, 114.3 mmol/l Cl−,
20.2 mmol/l HCO3
−, 0.3 mmol/l HPO4
2−, 0.4 mmol/l H2PO4
−, 10 mmol/l HEPES,
10 mmol/l glucose, pH 7.4) at 37 °C and gassed with 95% O2 and 5% CO2.
Basal transepithelial resistance of the tissue was determined by measuring
voltage response to pulse currents of 1 μA, and basal Isc was calculated from the
basal transepithelial resistance and the open-circuit transepithelial potential
difference. The tissue was subsequently short-circuited by voltage clamps,
resulting in a transepithelial potential difference of zero. After equilibration,
specific modulators were added to the mucosal (M) and/or serosal (S) sides of
the biopsy: 1. amiloride (1×10−4 M,M), 2. indomethacin (1×10−5 M,M+S), 3.
carbachol (1×10−4 M, S), 4. 8-bromo-cAMP (1×10−3 M, M+S) and forskolin
(1×10−5 M, S), 5. DIDS (2×10−4 M, M) and 6. histamine (5×10−4 M, S). All
chemicals were obtained from SIGMA-Aldrich, Steinheim, Germany.
Fig. 2. Metabolic labelling of rectal biopsies. After ICM two rectal suction biopsy
specimens were placed on a stainless steel grid and labelled biosynthetically with
15.4 MBq [35S]cysteine and 18.5 MBq [35S]methionine (Amersham Bios-
ciences) in methionine and cysteine deficient D-MEM medium (GIBCO)
supplemented with streptomycin and penicillin (GIBCO) following our protocol
established for the analysis of lactate-phlorizin hydrolase [24]. The biopsies were
incubated at 37 °C for 5 (lanes a, c, d, e) or 16 h (lane b). The biopsy specimens
were homogenized in the presence of 10 mM iodoacetamide, 20 mM PMSF,
20 μg/ml pepstatin and antipain, 100 μg/ml leupeptin and aprotonin and 500 μg/
ml soybean trypsin-inhibitor in Tris-buffer (20 mM Tris/HCl, 150 mMNaCl, pH
8). The lysis started by incubation with 0.03% SDS for 30 min, followed by 1%
(v/v) Triton X-100 and 0.5% (w/v) sodium deoxycholate for 30 min. After
centrifugation (16,000×g, 4 °C, 20 min) the supernatant was incubated with
protein A-sepharose (PAS, Amersham Biosciences) for 60 min. The immuno-
precipitation was carried out overnight except with the monoclonal antibodies
M3A7 (1:80, Chemicon, Temecula, USA), L12B4 (1:80, Chemicon, Temecula,
USA) and the polyclonal antibody R4531 (1:60) in the presence of PAS and
protein G-agarose (Sigma-Aldrich, lane a) or with the monoclonal antibody 570
linked to protein A agarose for (lane b, immunoprecipitation for 4 h), with the
monoclonal antibodies 596 (1:500) and L12B4(1:80) with protein G-agarose and
PAS (lane c). The monoclonal antibodies 570 and 596 were generously provided
by J. R. Riordan. SI in lane d and e was immunoprecipitated for 2 h with a mix of
monoclonal antibodies HBB1/219, HBB 2/619 and HBB 3/705, generously
provided by H. P. Hauri (Basel, Switzerland) and E. E. Sterchi (Berne,
Switzerland), in the presence of PAS. All pellets were washed several times with
washing buffers [1) PBS with 0.5% (v/v) Triton X-100 and 0.05% (w/v) sodium
deoxycholate and 2) 125 mM Tris, 500 mM NaCl, 10 mM EDTA, 0.5% (v/v)
TritonX-100, pH 8]. Immunoprecipitates were separated by 5%SDS-PAGE. The
gel was vacuum-dried and exposed to Biomax MR1 film (Kodak).
Fig. 3. Stability of metabolically labelled CFTR and SI. Rectal biopsies were
metabolically labelled with 35S-cysteine and 35S-methionine in methionine and
cysteine deficient D-MEM medium either continuously for 20 h (lanes a, c) or
for 5 h followed by incubation for 15 h in complete, non-radioactive medium
D-MEM/F-12 (GIBCO) supplemented with 5% fetal bovine serum (GIBCO,
lanes b, d). Lysis of tissue was performed with 0.10% SDS, followed by
immunoprecipitation with R453, L12B4 and M3A7. Separation by 5% SDS-
PAGE and detection by autoradiography. Metabolic labelling, lysis, immuno-
precipitation, separation and detection are described in detail in Fig. 2.
Fig. 4. Stability of CFTR in human rectal tissue at 26 and 37 °C. After ICM two
biopsies from the same proband were incubated overnight at either 26 or 37 °C
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e). Ideally 5% acrylamide gels are routinely used to ensure a
high resolution of the high-molecular weight isoforms of SI
[19]. Molecular weights of CFTR isoforms were calculated by
comparison with the molecular weights of β-galactosidase, α2-
macroglobulin, myosin and SI.1 The polyclonal antibody R453 was raised against two synthetic peptides
corresponding to amino acid 1–14 (MQRSPLEKASVVSK) of the N-terminus
of CFTR and to amino acid 1466–1480 (ALKEETEEEVQDTRL) of the C-
terminus of CFTR using the double X-system (Eurogentec, Seraing, Belgium).
After the third booster the serum was purified by affinity chromatography using
protein A-Sepharose.To confirm the identity of the CFTR bands immunopreci-
pitated by an antibody mixture of R453, M3A7 and L12B4,
alternatively the monoclonal anti-CFTR antibody 570 linked to
protein A-agarose or a mixture of the monoclonal anti-CFTR
antibodies 596 and L12B4 were chosen. Both immunoprecipi-
tations (Fig. 2, lanes b and c) showed a band of the expected 195
kDa in size. The pattern of further CFTR immunoreactive bands
of lower molecular weight, however, differed with the antibody
mixture used indicating that the epitopes are not equally
accessible in each CFTR isoform. Most efficient immunopre-
cipitations were obtained by utilizing a mixture of R453 within complete D-MEM/F-12 (5% fetal bovine serum). The lysed biopsies were
incubated with the pre-immune serum (PI) from R453 for 2 h. Immunopreci-
pitaton followed with R453 (1:60) in the presence of PAS. The immunodetection
was carried out in the presence of the monoclonal antibodies 596 and 570
(1:1000) and anti-mouse IgG HRP (Amersham Bioscience) using ECL Advance
(Amersham Bioscience) as detection reagent. Lysis and separation are described
in detail in Fig. 2.
Table 2
Survey of the experiments carried out with 35S-labelled human rectal biopsies















3 3×2 6 2 of 3
subjects






3 3×4 12 5 of 6
experiments b
Fig. 3
Incubation at 26°C and
37°C in parallel











1 1×2 2 1 of 1 subject Fig. 2,
lane b
Total 22 50 50
a A representative example of this type of experiment is shown in the
respective figure.
b For each volunteer, two biopsies were labelled with 35S continuously for
either 5 h or 20 h, respectively, and then processed, whereas the other two
biopsies were labelled with 35S for 5 h followed by incubation for 15 h with non-
radioactive medium.
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The latter two monoclonal antibodies have been used
previously for immunoprecipitation of CFTR from cell lines
[20,21], but were not efficient in immunoisolating CFTR from
human tissue (van Barneveld A., unpublished data).
To gain information about the maturation and turnover of the
CFTR protein bands in human rectal tissue, we labelled two
biopsies for 5 h followed by incubation with non-radioactive
medium for 15 h. As shown in Fig. 3, a qualitative difference in
the composition of the C-band of CFTR becomes evident
during the prolonged incubation time (lane b). While the C-form
appears as a heterogeneous doublet by continuous labelling
(lane a), the intensity of the upper band of the doublet had
decreased substantially 15 h after labelling had been terminated
and the C-form is converted to one single slightly diffuse band
of a similar size as the lower band of the doublet (lane b). A
qualitative difference in the biosynthetic features of the control
glycoprotein SI occurs as well. Here, the complex glycosylated
form of SI in the 5 h labelling time point was also processed to
an isoform of a reduced apparent molecular weight (compare
lane c with d). These data clearly show that the final maturation
events in the biosynthetic life cycle of the CFTR and SI proteins
implicate processing, most likely truncation, of the complex
glycosylated forms of these proteins. At least for CFTR, this
processing ends up with a more homogeneous glycosylation
pattern.
In cell lines, it was shown that the protein levels of CFTR are
higher at 26 °C than at 37 °C in mutant F508del CFTR, which to
some extent has been also shown for wild type CFTR [22]. We
examined this aspect by immunoblotting of CFTR with R453
using detergent extracts of biopsy samples that have been
incubated overnight at 26 °C or 37 °C (Fig. 4). Indeed,
incubation at 26 °C resulted in a dramatic increase in the proteinlevels of CFTR as assessed by the stronger signal of complex-
glycosylated CFTR (lane b) as compared to the protein isolated
from the tissue incubated at 37 °C (lane d). This observation is
not due to differential viability of the tissue at the two
temperatures because under our ex vivo culture condition
intestinal biopsies are known to be metabolically active for at
least 24 h [19,23,24]. Hence, the differential steady state
concentrations of the mutant F508del CFTR at 26 °C and 37 °C
[20] are also applicable to wild type CFTR. The immunoblot
analysis with the monoclonal CFTR antibodies 570 and 596
confirmed the size of complex-glycosylated band C of CFTR
determined in metabolic labelled rectal biopsies (Fig. 4). Table 2
provides information about the number of biopsies and subjects
applied to each type of experiment. Further, CFTR was
identified in 19 out of 22 analyzed specimens which is not
significantly different from a 100% detection rate (P = 0.12).
The aim of this study was to establish reproducible and
sensitive methods for the ex vivo analysis of human CFTR by
metabolic labelling or immunoblot whereby the CFTR expres-
sing tissue should be easily accessible by a safe, painless and
non-invasive procedure. These criteria apply to rectal suction
biopsies or nasal brushings to harvest epithelial cells. However,
the cell population from nasal brushings is heterogeneous and
hence this source is only suited for functional or immunocy-
tochemical single cell analysis [13,25,26], but not for CFTR
biochemistry.
Ethical considerations limited the maximal number of rectal
biopsies to be retrieved from one proband to four. Accordingly,
our protocols had to be optimized in their sensitivity and
specificity of immunochemical detection of CFTR. To this end,
two biopsies turned out to be sufficient to visualize CFTR by
immunoblot or metabolic labelling. The key to improving the
sensitivity and specificity was the combination of two or more
high-affinity CFTR antibodies. Mall and colleagues [8,9] were
the first to demonstrate that strong immunoreactive CFTR
signals with a high signal-to-noise ratio can be achieved if
CFTR is precipitated with a polyclonal antibody and the blots
are probed with a cocktail of monoclonal antibodies which
recognize separate CFTR epitopes. In our hands, the combina-
tion of our polyclonal antibody R453 for immunoprecipitation
with the highly sensitive monoclonal antibodies 570 and 596
developed for immunoblot in J. R. Riordan's laboratory
visualized immunoreactive CFTR bands from two biopsies
(Fig. 4).
In summary, we report for the first time on metabolic
labelling of CFTR ex vivo in human tissue. Two rectal biopsies
were sufficient to detect CFTR. The data indicate that the ex
vivo analysis of CFTR processing and trafficking should be
possible. A comparative study on biopsies retrieved from
F508del homozygous CF patients and non-CF healthy subjects
would be first priority.
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